Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Current Leases (2019 - 2025)

Tg Therapeutics (TGTX) has 7 years of Current Leases data on record, last reported at $1.0 million in Q4 2025.

  • For Q4 2025, Current Leases fell 9.77% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, down 9.77%, while the annual FY2025 figure was $1.0 million, 9.77% down from the prior year.
  • Current Leases reached $1.0 million in Q4 2025 per TGTX's latest filing, down from $1.1 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.6 million in Q3 2022 and bottomed at $1.0 million in Q4 2025.
  • Average Current Leases over 5 years is $1.4 million, with a median of $1.5 million recorded in 2021.
  • Peak YoY movement for Current Leases: grew 10.08% in 2022, then fell 19.99% in 2024.
  • A 5-year view of Current Leases shows it stood at $1.4 million in 2021, then increased by 10.02% to $1.6 million in 2022, then decreased by 8.54% to $1.4 million in 2023, then dropped by 19.99% to $1.2 million in 2024, then dropped by 9.77% to $1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $1.0 million in Q4 2025, $1.1 million in Q3 2025, and $1.1 million in Q2 2025.